Formulation and evaluation of alginate based mesalazine matrix tablets for intestinal delivery
Abstract
The aim of this study is to develop alginate based mesalazine matrix tablets for intestinal delivery. Sodium alginate is a biocompatible natural polymer, with pH sensitive gel forming ability. Matrix tablets of Mesalazine were prepared using Sodium alginate with three different concentrations by wet granulation method. The granules were evaluated for angle of repose, bulk density, tapped density, compressibility index and Hausners ratio. The tablets were subjected to weight variation, hardness, friability and drug content test. The in vitro release characteristics of mesalazine from alginate tablets were compared with those of the commercial product Asacol.
The cumulative amount of released drug of S3 formulation was found to be almost the same as the of commercial product in acidic and basic media. The release profiles were affected by variable concentrations of Sodium alginate and hence, the release of Mesalazine was prevented in upper GIT with increase in the proportion of Sodium alginate. Mesalazine-alginate matrix tablet formulations can deliver drug to the small and large intestine. Thus, it may be a promising system for the treatment of Ulcerative colitis.
References
Altamash I, Qureshi, Ruddell D. Cohen. 2005. Mesalamine Delivery system: Do they really make much difference? Adv. Drug Del. Rev., 57:281-302.
Aultons ME. 1998. Pharmaceutics: The science of dosage form design.2nd ed. London, England: Churchill Livingstone, 208.
Bajpai SK. 2004. Investigation of swelling/degradation behavior of alginate beads cross linked with Ca2+ and Ba2+ ions, Reac. Func. Poly., 59:129-140.
Hwang SJ, Park H, Park K. 1998. Gastric retentive drug delivery systems, Cric. Rev. Ther. Drug Carr. Systems 5:243-284.
Liberman HA, Lachman L and Kanig JL. 2001. The theory and practice of industrial pharmacy, 3rd ed. Bombay: Verghese publishing house. 184.
Liew CV, Chan LW, Ching PW. 2006. Evaluation of sodium alginate as drug release modifier in matrix tablets. Int. J. Pharm., 309:25-37.
Lin HY, Liang HF, Chung CK, Chen HW. 2005. Physical cross linked alginates/N,O carboxymethyl chotosan hydrogels with calcium for oral delivery of protein drugs, Biomaterials 26:2105-2113.
Melia CD, Davies MC, Mitchell JR. 1995. Structure and behavior in hydrophilic matrix sustained release dosage forms: 3. The influence of pH on the sustained-release performance and internal gel structure of sodium alginate matrices. Journal of Controlled Release. 33:143-152.
Pharmacopoeia of India. 1996. New Delhi: Ministry of Health and Family Welfare, Government of India, Controller of Publication;
Prakash A. 1999. oral delayed released Mesalazine, Drugs 57:383-408
Watts PJ and Illum L. 1997. Colonic Drug delivery, Drug Dev. Ind. Pharm., 23:893-913.
Wilding I. 2000. Sight specific drug delivery in gastrointestinal tract, cric. Rev. Ther. Drug Carr. Systems 17:557-620.
